Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells

Molecular Cancer Therapeutics

Volumn 3, Issue 11, 2004, Pages 1385-1396

  Liang, Huiyun ^a   Salinas, Richard A ^a   Leal, Belinda Z ^a   Kosakowska Cholody, Teresa ^b   Michejda, Christopher J ^b   Waters, Stephen J ^c   Herman, Terence S ^a   Woynarowski, Jan M ^a   Woynarowska, Barbara A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ANTINEOPLASTIC AGENT; BROMOBIMANE; CASPASE; CASPASE 2; CASPASE 3; CASPASE 4; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CYTOCHROME C; DNA FRAGMENT; INTERLEUKIN 1BETA CONVERTING ENZYME; IROFULVEN; PHOSPHATIDYLSERINE; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; DNA DEGRADATION; DRUG ANTAGONISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BICYCLO COMPOUNDS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; DNA FRAGMENTATION; ENZYME INHIBITORS; HUMANS; MALE; MITOCHONDRIA; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; SESQUITERPENES; SIGNAL TRANSDUCTION;

EID: 9444269351     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-808.
2. Woynarowska BA, Woynarowski JM. Preferential targeting of apoptosis in tumor versus normal cells. Biochim Biophys Acta 2002;1587: 309-17.
3. Woynarowski JM, Koester S, Woynarowska B, et al. Is drug-induced DNA damage sufficient for apoptosis induction? Proc AACR 1999; 40:736.
4. Akaboshi M, Kawai K, Maki H, et al. The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jpn J Cancer Res 1992; 83:522-6.
5. Herzig MCS, Arnett B, MacDonald JR, Woynarowski JM. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 1999;58:217-25.
6. Kelner MJ, McMorris TC, Montoya MA, et al. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines. Cancer Chemother Pharmacol 1999;44:235-40.
7. Urien S, Alexandre J, Raymond E, et al. Phase I population pharmacokinetics of irofulven. Anticancer Drugs 2003;14:353-8.
8. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. March 2003. Methods Find Exp Clin Pharmacol 2003;25:145-68.
9. MacDonald JR, Muscoplat CC, Dexter DL, et al. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 1997;57:279-83.
10. Kelner MJ, McMorris TC, Estes L, et al. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan. Leukemia 2000;14:136-41.
11. Kelner MJ, McMorris TC, Estes LA, et al. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft. Anticancer Drugs 2000;11:217-24.
12. Van Laar ES, Roth S, Weitman S, MacDonald JR, Waters SJ. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo. Anticancer Res 2004;24:59-65.
13. Van Laar ES, Weitman S, MacDonald JR, Waters SJ. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate 2004;59: 22-32.
14. Kelner MJ, McMorris TC, Estes L, et al. Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. Eur J Cancer 1998;34: 908-13.
15. Woynarowski JM, Napier C, Koester SK, et al. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol 1997;54:1181-93.
16. Woynarowska BA, Woynarowski JM, Herzig MCS, et al. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 2000;59: 1217-26.
17. Wang W, Waters SJ, MacDonald JR, et al. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells. Anticancer Res 2001;21: 1789-94.
18. Herzig MCS, Liang H, Johnson AE, Woynarowska B, Woynarowski JM. Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status. Breast Cancer Res Treat 2002;71:133-43.
19. Herzig MC, Trevino AV, Liang H, et al. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. Biochem Pharmacol 2003;65:503-13.
20. Woynarowska BA, Roberts K, Woynarowski JM, MacDonald JR, Herman TS. Targeting apoptosis by hydroxymethylacylfulvene in combination with γ radiation in prostate tumor cells. Radiat Res 2000;154: 429-38.
21. McMorris TC, Elayadi AN, Yu J, Hu Y, Kelner MJ. Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol. Drug Metab Dispos 1999;27:983-5.
22. McMorris TC, Yu J, Ngo HT, Wang H, Kelner MJ. Preparation and biological activity of amino acid and peptide conjugates of antitumor hydroxymethylacylfulvene. J Med Chem 2000;43:3577-80.
23. Dick RA, Yu X, Kensler TW. NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven. Clin Cancer Res 2004;10:1492-9.
24. Lawley PD, Phillips DH. DNA adducts from chemotherapeutic agents. Mutat Res 1996;355:13-40.
25. Woynarowska BA, Woynarowski JM, Liang H, et al. Irofulven binding and inactivation of purified and cellular redox-controlling proteins. Proc AACR 2004;45:A1510.
26. Henry-Mowatt J, Dive C, Martinou JC, James D. Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene 2004; 23:2850-60.
27. van Gurp M, Festjens N, van Loo G, Saelens X, Vandenabeele P. Mitochondrial intermembrane proteins in cell death. Biochem Biophys Res Commun 2003;304:487-97.
28. Cande C, Vahsen N, Garrido C, Kroemer G. Apoptosis-inducing factor (AIF): caspase-independent after all. Cell Death Differ 2004;11: 591-5.
29. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003;195:158-67.
30. Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 2003;15:691-9.
31. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004;23: 2785-96.
32. Costantini P, Belzacq AS, Vieira HL, et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 2000;19: 307-14.
33. McStay GP, Clarke SJ, Halestrap AP. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem J 2002;367: 541-8.
34. Joseph B, Marchetti P, Formstecher P, et al. Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. Oncogene 2002;21:65-77.
35. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
36. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis [see comments]. Science 1997;275:1132-6.
37. Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess δ ψ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997;411:77-82.
38. Woynarowska B, Woynarowski JM, Higdon AL, Munoz R. Induction of apoptosis in prostate tumor cells by hydroxymethylacylfulvene (HMAF) and oxaliplatin. Proc AACR 1999;40:488.
39. Jia L, Patwari Y, Srinivasula SM, et al. Bax translocation is crucial for the sensitivity of leukemic cells to etoposide-induced apoptosis. Oncogene 2001;20:4817-26.
40. Gao G, Dou QP. N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome c release and apoptotic cell death. J Cell Biochem 2000;80: 53-72.
41. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000;92: 1042-53.
42. Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999;144: 281-92.
43. Kuida K, Haydar TF, Kuan CY, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998;94:325-37.
44. Kim R, Tanabe K, Uchida Y, et al. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 2002;50:343-52.
45. Halestrap AP, Brennerb C. The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. Curr Med Chem 2003;10:1507-25.
46. Pallis M, Grundy M, Turzanski J, Kofler R, Russell N. Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status. Blood 2001;98:405-13.
47. Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J Immunol Methods 2000;243:167-90.
48. Honda T, Coppola S, Ghibelli L, et al. GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells. Cancer Gene Ther 2004;11:249-55.
49. Maser RS, Antoku K, Scully WJ Jr, Cho RL, Johnson DE. Analysis of the role of conserved cysteine residues in the bcl-2 oncoprotein. Biochem Biophys Res Commun 2000;277:171-8.
50. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie 2002;84:153-66.
51. Liang H, Herzig MCS, Salinas R, et al. Pro-oxidative distortion of the cellular redox-homeostasis in irofulven-induced apoptosis. Clin Cancer Res 2001;7:3723s.
52. Chen Q, Gong B, Almasan A. Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis. Cell Death Differ 2000;7:227-33.
53. Gao CF, Ren S, Zhang L, et al. Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis. Exp Cell Res 2001;265:145-51.
54. Katoh I, Tomimori Y, Ikawa Y, Kurata S. Dimerization and processing of procaspase-9 by redox stress in mitochondria. J Biol Chem 2004;279: 15515-23.
55. Zamzami N, Marzo I, Susin SA, et al. The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition. Oncogene 1998;16:1055-63.